Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom (MET52)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03632720 |
Recruitment Status :
Recruiting
First Posted : August 15, 2018
Last Update Posted : January 6, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Meningococcal Infection | Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine Biological: Meningococcal group B vaccine Biological: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine Biological: Human rotavirus RIX4414 strain vaccine Biological: Pneumococcal 13-valent polysaccharide conjugate vaccine | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 700 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Using a 1+1 Schedule in a National Immunization Schedule Having a Meningococcal Group B Vaccine as Standard of Care |
Actual Study Start Date : | October 10, 2018 |
Estimated Primary Completion Date : | June 2022 |
Estimated Study Completion Date : | June 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Group 1
MenACYW conjugate vaccine at 3 months and at 12 to 13 months of age; meningococcal Group B vaccine at 2, 4, and 12 to 13 months of age; routine pediatric vaccines
|
Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine
Pharmaceutical form: solution for injection; route of administration: intramuscular, 0.5 mL Biological: Meningococcal group B vaccine Pharmaceutical form: solution for injection; route of administration: deep intramuscular, 0.5 mL Biological: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL Biological: Human rotavirus RIX4414 strain vaccine Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL Biological: Pneumococcal 13-valent polysaccharide conjugate vaccine Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL |
Experimental: Group 2
MenACYW conjugate vaccine at 3 months and at 12 to 13 months of age; meningococcal Group B vaccine at 2 and 4 months of age; routine pediatric vaccines
|
Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine
Pharmaceutical form: solution for injection; route of administration: intramuscular, 0.5 mL Biological: Meningococcal group B vaccine Pharmaceutical form: solution for injection; route of administration: deep intramuscular, 0.5 mL Biological: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL Biological: Human rotavirus RIX4414 strain vaccine Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL Biological: Pneumococcal 13-valent polysaccharide conjugate vaccine Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL |
Active Comparator: Group 3
Meningococcal Group B vaccine at 2, 4, and 12 to 13 months of age; routine pediatric vaccines
|
Biological: Meningococcal group B vaccine
Pharmaceutical form: solution for injection; route of administration: deep intramuscular, 0.5 mL Biological: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL Biological: Human rotavirus RIX4414 strain vaccine Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL Biological: Pneumococcal 13-valent polysaccharide conjugate vaccine Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL |
- Antibody titers ≥ 1:8 against meningococcal serogroups A, C, Y, and W [ Time Frame: Day 30 ]% of participants achieving antibody titers ≥ predefined threshold of 1:8. Titers are measured by serum bactericidal assay using human complement (hSBA)
- Antibody titers against meningococcal serogroups A, C, Y, and W [ Time Frame: Day 30 ]Antibody titers expressed as geometric mean titers (GMTs)
- Number of participants reporting solicited injection site reactions or systemic reactions [ Time Frame: Day 7 ]Injection site reactions: pain, erythema, and swelling; Systemic reactions: fever, vomiting, crying abnormal, drowsiness, appetite lost, and irritability

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 56 Days to 89 Days (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion criteria :
- Aged ≥ 56 to ≤ 89 days on the day of the first study visit
- Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg (or 5 lb and 8 oz)
- Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative (and by an independent witness if required by local regulations)
- Subject and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures
Exclusion criteria:
- Participation at the time of study enrollment (or in the 4 weeks preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
- Receipt of any vaccine in the 4 weeks preceding the first trial vaccination (at Visit 1) or planned receipt of any vaccine in the 4 weeks before and/or following any trial vaccination except for influenza vaccination, which may be received at a gap of at least 2 weeks before or 2 weeks after any study vaccines. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.
- Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine containing serogroups A, C, W, or Y; or meningococcal B serogroup-containing vaccine)
- Previous vaccination (before Visit 1) with any pneumococcal, diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b (Hib), poliovirus, and/or rotavirus vaccines. Receipt of Bacille Calmette Guerin (BCG) vaccine at birth is acceptable.
- Receipt of immune globulins, blood or blood-derived since birth
- Known or suspected congenital or acquired immunodeficiency, including Severe Combined Immunodeficiency disorder (SCID); or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks) since birth
- History of any neurologic disorders, including any seizures and progressive neurologic disorders or encephalopathy
- History of Neisseria meningitidis infection, confirmed either clinically, serologically, or microbiologically
- History of diphtheria, tetanus, pertussis, poliomyelitis, Hib, hepatitis B, Streptococcus pneumoniae, and/or rotavirus infection or disease
- At high risk for meningococcal infection during the trial (specifically, but not limited to, subjects with persistent complement deficiency, with anatomic or functional asplenia, or subjects travelling to countries with high endemic or epidemic disease)
- History of Guillain-Barré syndrome
- Known systemic hypersensitivity to any of the vaccine components, or history of a life- threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances including neomycin, kanamycin, polymyxin, formaldehyde, and latex
- Hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency
- History of intussusception or uncorrected congenital malformation of the gastrointestinal tract that would predispose to intussusception
- Verbal report of thrombocytopenia, contraindicating intramuscular vaccination in the investigator's opinion
- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
- Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives, including planning to leave the area of the study site before the end of the study
- Moderate or severe acute illness/infection (according to investigator judgment), or febrile illness (temperature ≥ 38.0 C), or diarrhea or vomiting on the day of vaccination. A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.
- Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03632720
Contact: Trial Transparency email recommended (Toll free number for US & Canada) | 800-633-1610 ext 1 then # | RegistryContactUS@sanofipasteur.com |
United Kingdom | |
Investigational Site Number 8260001 | Recruiting |
Bristol, United Kingdom, BS2 8AE | |
Investigational Site Number 8260010 | Recruiting |
Exeter, United Kingdom, EX2 5DW | |
Investigational Site Number 8260018 | Recruiting |
Gloucester, United Kingdom, GL1 3NN | |
Investigational Site Number 8260011 | Recruiting |
Ivybridge, United Kingdom, PL21 OAJ | |
Investigational Site Number 8260002 | Recruiting |
London, United Kingdom, SW 17 ORE | |
Investigational Site Number 8260024 | Recruiting |
Newquay, United Kingdom, TR7 1RU | |
Investigational Site Number 8260009 | Recruiting |
Penzance, United Kingdom, TR19 7HX | |
Investigational Site Number 8260017 | Recruiting |
Poole, United Kingdom, BH15 2HX | |
Investigational Site Number 8260016 | Recruiting |
Portsmouth, United Kingdom, PO6 3LY | |
Investigational Site Number 8260003 | Recruiting |
Southampton, United Kingdom, SO16 6YD | |
Investigational Site Number 8260006 | Recruiting |
Taunton, United Kingdom, TA1 5DA | |
Investigational Site Number 8260013 | Recruiting |
Torpoint, United Kingdom, PL11 2TB | |
Investigational Site Number 8260021 | Recruiting |
Waterlooville, United Kingdom, PO8 8DL |
Study Director: | Clinical Sciences & Operations | Sanofi Pasteur, a Sanofi Company |
Responsible Party: | Sanofi Pasteur, a Sanofi Company |
ClinicalTrials.gov Identifier: | NCT03632720 |
Other Study ID Numbers: |
MET52 2017-004520-30 ( EudraCT Number ) U1111-1183-6530 ( Other Identifier: UTN ) |
First Posted: | August 15, 2018 Key Record Dates |
Last Update Posted: | January 6, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/ |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Meningococcal Infections Meningitis Neisseriaceae Infections Gram-Negative Bacterial Infections Bacterial Infections |
Central Nervous System Diseases Nervous System Diseases Vaccines Immunologic Factors Physiological Effects of Drugs |